Blinatumomab

Hodgkins Lymphoma

St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 65/ 100

Competitive context

149 Active assets in the Hodgkins Lymphoma cohort.

Asset / Sponsor	Phase	Rating
CYCLOSPORIN A City of Hope Medical Center	Phase 3	BBB
METHOTREXATE Therapeutic Advances in Childhood Leukemia Consortium	Phase 3	BBB
CARMUSTINE VIVUS LLC	Phase 2	BBB
Carboplatin St. Petersburg State Pavlov Medical University	Phase 2	BBB
Everolimus OHSU Knight Cancer Institute	Phase 2	BBB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant

BBB

Indicative ·

72 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BBB

Indicative ·

72 / 100

Precursor B-Cell Acute Lymphoblastic LeukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.